

To the Press:

Exiqon A/S
Skelstedet 16
2950 Vedbæk
Denmark

Phone: +45 4566 0888
Fax: +45 4566 1888
exiqon@exiqon.com
www.exiqon.com
CVR/Tax Id: 18 98 44 31

23 May 2011

Exiqon announces presentation of results at the 2011 ASCO Annual meeting in Chicago showing the potential use of microRNAs as biomarkers in drug development together with a major pharmaceutical company and the National Cancer Center, Singapore

Exiqon A/S (Copenhagen:EXQ) today announced that results from a diagnostic program on the potential of using circulating microRNAs in serum as companion diagnostic biomarkers has been selected for presentation at the 2011 ASCO meeting to be held June 3-6 in Chicago.

The title of the work is: "The potential of circulating microRNA (miRNA) levels as a biomarker in drug development: An analysis of tumor-serum samples from patients on a phase I trial of saracatinib-paclitaxel (P) carboplatin (C)". Abstract No: 10548 Citation: J Clin Oncol 29: 2011 (suppl; abstr 10548).

"The selection for presentation at the ASCO is a reflection of the great progress being made in demonstrating the utility of miRNAs present in blood derived serum or plasma as biomarkers.", says Adam Baker, VP of Diagnostics at Exiqon.

For more information, please visit the 2011 ASCO Annual Meeting home page at:

<http://chicago2011.asco.org/>

Abstract page:

http://abstract.asco.org/AbstView_102_78314.html

Additional information:

Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)

Adam Baker, Vice President Diagnostics & Pharmaceutical Alliances, email: adam@exiqon.com, tel. +45 4565 0986 (cell: +45 4090 2153)

About Exiqon

Exiqon's products are based on the proprietary LNA™ technology. This technology offers unique advantages for detection of miRNA biomarkers for life science researchers, drug developers and cancer treating physicians working towards personalizing medicine. Exiqon operates in two business areas: Exiqon Life Sciences has established a position for itself as one of the market's leading providers of miRNA research products for miRNA analysis in cells and bodyfluids. Our research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Life Sciences is also collaborating with pharmaceutical companies in their effort to target new medicines based on miRNA as biological markers. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions. Exiqon is listed on the NASDAQ OMX in Copenhagen. For more information about us, please visit www.exiqon.com.